Logo image of ESPR

ESPERION THERAPEUTICS INC (ESPR) Stock Fundamental Analysis

NASDAQ:ESPR - Nasdaq - US29664W1053 - Common Stock - Currency: USD

1.22  +0.06 (+5.17%)

After market: 1.23 +0.01 (+0.82%)

Fundamental Rating

2

Overall ESPR gets a fundamental rating of 2 out of 10. We evaluated ESPR against 195 industry peers in the Pharmaceuticals industry. ESPR may be in some trouble as it scores bad on both profitability and health. ESPR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ESPR had negative earnings in the past year.
In the past year ESPR has reported a negative cash flow from operations.
ESPR had negative earnings in each of the past 5 years.
ESPR had a negative operating cash flow in each of the past 5 years.
ESPR Yearly Net Income VS EBIT VS OCF VS FCFESPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

ESPR has a Return On Assets (-47.29%) which is in line with its industry peers.
Industry RankSector Rank
ROA -47.29%
ROE N/A
ROIC N/A
ROA(3y)-70.33%
ROA(5y)-64.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ESPR Yearly ROA, ROE, ROICESPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

ESPR has a better Gross Margin (65.30%) than 72.31% of its industry peers.
In the last couple of years the Gross Margin of ESPR has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for ESPR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5YN/A
ESPR Yearly Profit, Operating, Gross MarginsESPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

1

2. Health

2.1 Basic Checks

ESPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ESPR has been increased compared to 1 year ago.
Compared to 5 years ago, ESPR has more shares outstanding
ESPR has a better debt/assets ratio than last year.
ESPR Yearly Shares OutstandingESPR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ESPR Yearly Total Debt VS Total AssetsESPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -6.34, we must say that ESPR is in the distress zone and has some risk of bankruptcy.
ESPR has a Altman-Z score of -6.34. This is in the lower half of the industry: ESPR underperforms 65.64% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.34
ROIC/WACCN/A
WACC9.13%
ESPR Yearly LT Debt VS Equity VS FCFESPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

2.3 Liquidity

A Current Ratio of 1.18 indicates that ESPR should not have too much problems paying its short term obligations.
With a Current ratio value of 1.18, ESPR is not doing good in the industry: 78.97% of the companies in the same industry are doing better.
ESPR has a Quick Ratio of 1.18. This is a bad value and indicates that ESPR is not financially healthy enough and could expect problems in meeting its short term obligations.
ESPR has a Quick ratio of 0.81. This is amonst the worse of the industry: ESPR underperforms 82.56% of its industry peers.
Industry RankSector Rank
Current Ratio 1.18
Quick Ratio 0.81
ESPR Yearly Current Assets VS Current LiabilitesESPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

ESPR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.19%, which is quite good.
The Revenue has grown by 12.96% in the past year. This is quite good.
Measured over the past years, ESPR shows a quite strong growth in Revenue. The Revenue has been growing by 17.50% on average per year.
EPS 1Y (TTM)19.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-161.76%
Revenue 1Y (TTM)12.96%
Revenue growth 3Y61.84%
Revenue growth 5Y17.5%
Sales Q2Q%-52.81%

3.2 Future

The Earnings Per Share is expected to grow by 40.32% on average over the next years. This is a very strong growth
ESPR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 28.11% yearly.
EPS Next Y15.78%
EPS Next 2Y1.34%
EPS Next 3Y24.55%
EPS Next 5Y40.32%
Revenue Next Year4.4%
Revenue Next 2Y0.63%
Revenue Next 3Y11.63%
Revenue Next 5Y28.11%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ESPR Yearly Revenue VS EstimatesESPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ESPR Yearly EPS VS EstimatesESPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ESPR. In the last year negative earnings were reported.
Also next year ESPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ESPR Price Earnings VS Forward Price EarningsESPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ESPR Per share dataESPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as ESPR's earnings are expected to grow with 24.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.34%
EPS Next 3Y24.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ESPR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ESPERION THERAPEUTICS INC

NASDAQ:ESPR (6/6/2025, 8:00:02 PM)

After market: 1.23 +0.01 (+0.82%)

1.22

+0.06 (+5.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners66.23%
Inst Owner Change-9.92%
Ins Owners0.42%
Ins Owner Change10.65%
Market Cap241.80M
Analysts77.14
Price Target5.9 (383.61%)
Short Float %14.17%
Short Ratio4.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.74%
Min EPS beat(2)-32.97%
Max EPS beat(2)27.5%
EPS beat(4)2
Avg EPS beat(4)-16.23%
Min EPS beat(4)-75.67%
Max EPS beat(4)27.5%
EPS beat(8)5
Avg EPS beat(8)73.6%
EPS beat(12)7
Avg EPS beat(12)48.7%
EPS beat(16)11
Avg EPS beat(16)40.01%
Revenue beat(2)2
Avg Revenue beat(2)13.64%
Min Revenue beat(2)10.02%
Max Revenue beat(2)17.27%
Revenue beat(4)3
Avg Revenue beat(4)19.58%
Min Revenue beat(4)-1.37%
Max Revenue beat(4)52.41%
Revenue beat(8)7
Avg Revenue beat(8)20.63%
Revenue beat(12)8
Avg Revenue beat(12)12.82%
Revenue beat(16)11
Avg Revenue beat(16)11.95%
PT rev (1m)-5.55%
PT rev (3m)-9.4%
EPS NQ rev (1m)-11.43%
EPS NQ rev (3m)-10.41%
EPS NY rev (1m)-979.09%
EPS NY rev (3m)-385.72%
Revenue NQ rev (1m)4.35%
Revenue NQ rev (3m)7.96%
Revenue NY rev (1m)-1.54%
Revenue NY rev (3m)-1.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.93
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)-0.24
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS1.31
BVpS-2.15
TBVpS-2.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.29%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.3%
FCFM N/A
ROA(3y)-70.33%
ROA(5y)-64.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5YN/A
F-Score2
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 274.16%
Cap/Sales 0.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.18
Quick Ratio 0.81
Altman-Z -6.34
F-Score2
WACC9.13%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-161.76%
EPS Next Y15.78%
EPS Next 2Y1.34%
EPS Next 3Y24.55%
EPS Next 5Y40.32%
Revenue 1Y (TTM)12.96%
Revenue growth 3Y61.84%
Revenue growth 5Y17.5%
Sales Q2Q%-52.81%
Revenue Next Year4.4%
Revenue Next 2Y0.63%
Revenue Next 3Y11.63%
Revenue Next 5Y28.11%
EBIT growth 1Y-15.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-122.85%
EBIT Next 3Y-16.98%
EBIT Next 5Y-4.02%
FCF growth 1Y47.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.37%
OCF growth 3YN/A
OCF growth 5YN/A